CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
<h3>Background</h3><p dir="ltr">Asymptomatic carriers of leucine-rich repeat kinase 2 (LRRK<sub>2</sub>) gene mutations constitute an ideal population for discovering prodromal biomarkers of Parkinson’s disease (PD). In this study, we aim to identify CSF candi...
محفوظ في:
| المؤلف الرئيسي: | Nour K. Majbour (8809316) (author) |
|---|---|
| مؤلفون آخرون: | Jan O. Aasly (7930109) (author), Eldbjørg Hustad (8809319) (author), Mercy A. Thomas (8809322) (author), Nishant N. Vaikath (2901785) (author), Naser Elkum (79418) (author), Wilma D. J. van de Berg (8809325) (author), Takahiko Tokuda (105837) (author), Brit Mollenhauer (482499) (author), Henk W. Berendse (8809328) (author), Omar M. A. El-Agnaf (8809331) (author) |
| منشور في: |
2020
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
حسب: Nour K. Majbour (8809316)
منشور في: (2016) -
Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
حسب: Ilham Y. Abdi (14778898)
منشور في: (2021) -
Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
حسب: Nour K. Majbour (8809316)
منشور في: (2017) -
Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans
حسب: Kevin S. Chen (9201767)
منشور في: (2021) -
Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
حسب: Nour Majbour (3528548)
منشور في: (2022)